Company ProfilePremium

Corentec Co., Ltd.

Company Profile Analysis

Ticker: 104540.KQ

ESOMAR 23 Corporate BadgeISO Certifications Badge
Corentec Co., Ltd. - Company showcase

Year Founded & Workforce

2000

172 Employees

Corentec Co., Ltd. logo

Corentec Co., Ltd. Employee Contacts

We don't hold contact details for this company yet — you can request them.

Request Employee Contacts

Corentec Co., Ltd. Overview

Corentec is Korea's first dedicated manufacturer of artificial joints and its domestic share leader in total hip arthroplasty. Its core portfolio is primary and revision hip and knee replacement systems: BENCOX/BENFIX hips, and LOSPA and EXULT knees. Shoulder (CORALIS), spinal fixation (LOSPA IS), sports-medicine and trauma lines complement them.

The company differentiates on proprietary implant surface technologies, MAO (micro-arc oxidation) and DMT coatings. It combines a cost-competitive Korean manufacturing base with regulatory clearances in the US (FDA), Japan (MHLW), India (CDSCO), Mexico, Brazil and about 20 export markets.

The group also holds a 51.2% stake in Sun Healthcare International. That subsidiary owns a US ambulatory surgery centre in Huntington Beach, California, and runs Korean corporate health-screening and medical-device distribution businesses.

At about KRW 100bn of revenue, Corentec is a sub-scale niche challenger to the global "big four" orthopaedic majors. Its equity story rests on export growth, profitability normalisation after the 2024 trough, and deleveraging. Governance volatility, including four CEO changes since 2023, is the main overhang.


What the company does

Corentec designs, manufactures and sells orthopaedic implants and the associated surgical instruments. Joint reconstruction is the core: hip and knee implants account for the large majority of revenue.

Product lines (corentec.com product menu; Morningstar; Simply Wall St):

  • Hip: BENCOX, BENFIX

  • Knee: LOSPA, EXULT

  • Shoulder: CORALIS

  • Spine: LOSPA IS

  • Sports medicine: CorLock suture anchor

  • Trauma: LCfit HTO plate, Optirad volar plate

Manufacturing is concentrated at the Cheonan plant in South Chungcheong Province.

Reported business segments

Segment (as reported)Share of Q2 2026 revenueContents
Artificial joints (인공관절)80%Corentec parent; hip, knee, shoulder, spine, sports medicine, trauma implants and instruments; Korea and exports including the US
Medical-device wholesale (의료기기도매)16%Distribution activity, attributed to subsidiary Sun Healthcare International, whose business model includes medical-device distribution (TheVC)
Information services & ambulatory surgery centre (정보이용 및 외래수술센터)4%Sun Healthcare's B2B health-screening platform and the Sun Surgery Center Huntington ASC in California

Revenue mix by segment, Q2 2026 (Butler, from the H1 2026 report):

Revenue and business model

Model elementCharacterisation
Product vs servicePredominantly product sales of implants (about 80%), plus distribution (about 16%) and services (about 4%: health-screening intermediation, ASC procedures)
Subscription / licensingNone material disclosed
PricingIn Korea, implant pricing is governed by National Health Insurance reimbursement ceilings (structural industry feature; company-specific price lists not disclosed). Export pricing is set with distributors, e.g. contract unit prices under the Biortotec (Mexico) supply agreement (SmartToday, Mar 2023)
ChannelDomestic: hospital and dealer (대리점) networks. Exports: exclusive or regional distributors (Mexico: Biortotec; India: three regional distributors). US: subsidiary Corentec America (company releases; Medigate 2022)
Value-chain positionVertically integrated designer and manufacturer (design, machining, surface treatment, sterilisation and packaging at Cheonan). Downstream exposure through the ASC, the only US ASC owned by a joint-implant maker, per the company in 2022 (Dealsite, Jul 2022)

Customers and end-markets

Customers: orthopaedic surgeons, hospitals (tertiary to secondary), ASCs and national distributors.

End-markets: primary and revision total hip and knee arthroplasty, shoulder arthroplasty, spinal fusion, sports-medicine soft-tissue repair, and trauma fixation.

Demand driver: population ageing in Korea and export markets (Korean Investing.com commentary, 2020; company IR, 2018).

Company self-description vs independent characterisation

Company description. In its FY2025 results release (10 Feb 2026), the company calls itself Korea's first specialist artificial-joint manufacturer since its founding in 2000. It says it develops hip, knee and spinal-fixation devices, and that FY2025 marked a qualitative change in its earnings structure.

Independent characterisation. Corentec is a single-plant, export-leveraged orthopaedic implant maker with a defensible Korean hip franchise. The franchise is reported as the domestic hip share leader for seven consecutive years as of 2023 (KED Global, Jul 2023), but the company is No. 3 in Korean knees (Edaily, 2023). Exports run at about 40% of revenue, with the US the largest export market, at roughly KRW 14bn in 2023 (Pharm Edaily, 2024).

From 2022 to 2024 management tried to become a "comprehensive healthcare company":

  • dental prosthetics licensing from RODO Medical;

  • the Sun Healthcare ASC and screening business;

  • Woosung Pharmaceutical (generic injectables).

The pharmaceutical leg was reversed in March 2025, and the China subsidiary was liquidated in 2024. Since then the company has refocused on the implant core under a profitability and deleveraging agenda.

Strategy

Stated strategic themes (company releases 2025–2026)

  1. Global market expansion. US, Latin America and Southeast Asia are the priority regions (Q1 2026 release).

  2. Product competitiveness. Portfolio diversification and advanced surface-treatment technology (Q1 2026 release; Nov 2025 release).

  3. Profitability and cost efficiency. The company frames FY2025 as a structural earnings turnaround that should support a stable profit base (FY2025 release).

  4. Partnership-led distribution. Exhibitions (JOA Tokyo, WHX Miami, SBOT Brazil, GHE Riyadh) and distributor MOUs (Nov 2025 release).

Initiatives in the last 24 months

DateInitiativeDetail / targetSource
H2 2024China exitLiquidation of Corentec China to concentrate on the USDailymedi, 2024
2,024Organisational resetDissolution of Future Strategy and New Growth offices created under CEO KangDailymedi, 2024
Mar 2025Portfolio pruningWoosung Pharmaceutical sold for KRW 10bnMedigate, Mar 2025
Apr 2025US knee line extensionEXULT UCR launch; USD 6.05M (2025) → 7.86M (2026) → USD 10M+ (2027) expectation, about 30%+ annual growthCorentec/Yakup, Apr 2025
May 2025FY2025 joint revenue targetKRW 77.8bn (+20%)Corentec/BioTimes, May 2025
2,025DeleveragingBond repayments of KRW 28.9bn; net debt cut to KRW 8.5bnValueline
Oct–Nov 2025Market developmentGHE Riyadh; Biortotec USD 15M three-year MOU (Mexico)Corentec, Nov 2025
Nov 2025IPTwo new knee patent filings (universal tibial implant; femoral implant holder); 96 patents heldCorentec, Nov 2025
2024 (national R&D)Technology bets3D printing, artificial ankle, clinician-needs customisationTheVC
Dec 2025LeadershipMedtech-industry CEO (Hyun) appointed, after a battery-industry quality executive (Koo)Dealsite; Etoday

Medium-term guidance. No formal consolidated guidance for FY2026 or beyond was found. The only quantitative management targets retrieved are the EXULT UCR US sales trajectory and the FY2025 joint-segment target of KRW 77.8bn. Achievement of the latter was not disclosed separately.

ESG commitments. None disclosed beyond an ethics-management (윤리경영) policy page on the corporate website.

Products & Services

Pricing is not publicly disclosed for any product. Korean reimbursement-based pricing applies domestically.

Artificial joints — Hip

ProductDescription / capabilitiesTarget customerRegulatory / launch notesSource
BENCOX Hip SystemFlagship hip; the line behind domestic hip share leadershipArthroplasty surgeons, Korea and exportKorea; US; Japan MHLW approval Jul 2023; India CDSCO May 2022; MexicoKED Global 2023; Medigate 2022
BENFIX Hip SystemSecond hip platformSameKorea; India CDSCO 2022Medigate 2022; corentec.com
Mirabo Z CupAcetabular cup with DMT coatingSameMexico launch prepared in 2023SmartToday, Mar 2023
Bipolar hipHemiarthroplasty optionFracture and hemi casesOffered in the US by Corentec AmericaBecker's Spine; ODT
Hip portfolio breadthEight hip product types—As of 2023Pharm Edaily, Apr 2023

Core technology: MAO (micro-arc oxidation) surface treatment, designed to strengthen bone–implant bonding in cementless fixation (Pharm Edaily, 2023; AsiaToday, 2010).

Artificial joints — Knee

ProductDescription / capabilitiesRegulatory / launch notesSource
LOSPA TKR System (Primary & Revision)Total knee system with primary and revision optionsKorea; India CDSCO 2022; MexicoMedigate 2022; SmartToday 2023
LOSPA II Knee SystemNext-generation LOSPAUS FDA clearance (2019)Edaily, 2019
EXULT Knee SystemTotal knee with four tibial-insert options: CR (cruciate retaining), PS (posterior stabilised), CPS (constrained PS) and UCR (ultra-congruent and cruciate retaining)UCR FDA clearance Apr 2025; US launch Apr 2025Corentec/Yakup, Apr 2025
EXULT UCR insertOne insert usable whether the surgeon resects or retains the PCLCompany revenue expectations: about USD 6.05M (2025), 7.86M (2026), 10M+ (2027)Corentec, Apr–May 2025

Shoulder, spine, sports medicine, trauma, other

LineProductNotesSource
ShoulderCORALIS Total & Reverse Shoulder SystemIndia CDSCO 2022; US clearance in process (2024)Medigate 2022; Pharm Edaily 2024
SpineLOSPA IS spinal (pedicle-screw) systemFDA cleared; supplied to MexicoPharm Edaily 2024; SmartToday 2023
Sports medicineCorLock Suture AnchorListed on company product menucorentec.com 2026
TraumaLCfit HTO plate system; Optirad volar plate systemHigh tibial osteotomy and distal radius platesSimply Wall St profile
AnkleTotal ankle replacementUnder MFDS (Korea) review in 2023; national R&D project in 2024; commercial status not confirmedPharm Edaily 2023; TheVC
Bone substitutesBone-substitute productsListed by GlobalData/CB Insights profile; details not disclosedCB Insights
DentalRODO Medical cement-free implant prostheticsKorean exclusive distribution plus technology transfer (2022); current commercial scale not disclosedEtoday, Mar 2022
InstrumentsSurgical instrument setsSold or loaned with implants; US instruments also soldODT

Services (subsidiary)

ServiceDescriptionScaleSource
Corporate health-screening platformCustomised screening, vaccination and psychological counselling for employees via about 600 partner hospitalsAbout 111 corporate clients and 600k people per year (2022); 61 companies and about 220k people (2023 figure)Dealsite 2022; Pharm Edaily 2023
Sun Surgery Center Huntington (US ASC)Same-day joint-replacement surgery centre; discharge in 2–24 hours700+ surgeries and procedures per year (2022)Dealsite, Jul 2022
Medical-device distributionWholesale distribution (about 16% of Q2 2026 group revenue)—Butler; TheVC

Financial Narrative

Income statement

Sources: Butler (revenue, OP, net income FY2021–FY2025, as reported), FnGuide (OP margins) and company release (FY2025 OP KRW 9.02bn). FY2024 is shown as originally reported.

FY2025 D&A of KRW 5.42bn is PP&E depreciation of 4.64 plus intangible amortisation of 0.78 (Valueline cash-flow statement). EBITDA is OP plus D&A.

Corentec pays no dividend (Stockopedia).

FY2024 restated base. The company states FY2025 revenue grew 17.3% and OP grew 167.2%. That implies a restated FY2024 (excluding Woosung) of about KRW 85.6bn revenue and about KRW 3.4bn OP (Corentec release, 10 Feb 2026; arithmetic derived).

Revenue CAGR FY2021–FY2025 (as reported): about 22.5%. It is heavily inflated by the 2022–2023 acquisitions.

Commentary.

2022–2023: Revenue roughly doubled from KRW 44.6bn to 92.0bn. Drivers were organic export growth (SE Asia and Latin America up 327.7% YoY in Q2 2022; US up 33.1%; Edaily Aug 2022) and the consolidation of Sun Healthcare (H2 2022) and Woosung (from May 2023). Operating margin held at 7.7–9.1%.

2024 trough: Revenue was flat at KRW 93.7bn, OP fell 45% to KRW 3.9bn, and the company booked a net loss of KRW 1.3bn. Contributing factors in the record: the cost of the "comprehensive healthcare" build-out under CEO Kang (dedicated strategy units later dissolved), the China business difficulties that led to liquidation, interest on about KRW 51bn of gross debt, and leadership disruption, with the CEO seat vacant for about three months in 2024 (Dailymedi; Daum/ChosunBiz; News1).

2025 inflection: OP rebounded to KRW 9.0bn (9.0% margin) on implant growth and cost efficiencies. The parent alone posted Q1 2025 OP up 366% YoY to KRW 1.65bn on revenue of KRW 18.0bn (+19%) (Corentec/BioTimes, May 2025). Net income returned to KRW 7.0bn, partly helped by the Woosung disposal.

1H 2026: - Revenue was KRW 50.4bn (Q1 24.6 + Q2 25.8), about +9% YoY.

  • Consolidated OP was KRW 2.35bn (Q1 0.89 + Q2 1.46), below the prior year's pace.

  • Management attributed the Q1 weakness to consolidated subsidiaries and said the parent's core business kept growing (company/CB Insights news, May 2026). This shows the subsidiaries are now a drag on group margin.

Balance sheet

Source: Valueline/DataHero consolidated statements.

Definitions: total financial debt is short-term borrowings + short-term bonds + current portion of LT debt + LT borrowings + CBs, excluding lease and other financial liabilities. Net debt is that debt minus cash and short-term financial assets. Working capital is current assets minus current liabilities.

Commentary.

Deleveraging in 2025: Gross debt fell from KRW 51.1bn to 29.3bn and net debt from 31.8bn to 8.5bn. Bond repayments of KRW 28.9bn in FY2025 (Valueline cash-flow statement) retired most of the 8th and 9th CBs.

Funding sources: The deleveraging was funded by Woosung sale proceeds (KRW 9bn cash plus a KRW 1bn CB; News1) and by operating cash flow, which rose mainly through inventory liquidation: inventories fell from 45.2 to 32.6.

Equity restructuring: Retained earnings swung from a KRW 46.3bn deficit (FY2024) to a KRW 10.1bn surplus (FY2025), while capital surplus fell from KRW 111.1bn to 61.2bn. The pattern is consistent with share premium being used to eliminate accumulated losses. That is an analytical inference; the mechanics should be confirmed in the FY2025 business report.

H1 2026: Share count rose from 12.79M to 13.41M, and share capital and share premium rose. This is consistent with conversion of remaining CBs (inference).

Receivables quality: Trade receivables of KRW 42.1bn on revenue of KRW 100.4bn imply about 153 days of sales outstanding (FY2025), long even for the Korean dealer-and-hospital channel.

Cash flow

Source: Valueline/DataHero, trailing-twelve-month values at each fiscal year-end.

Valueline's own FCF metric reads KRW 20.58bn for FY2025 and 13.22bn for TTM Jun 2026. Corentec pays no ordinary dividend, so the KRW 0.43bn of dividends paid is assumed to go to subsidiary minority holders (inference).

Commentary. FY2025 OCF of KRW 26.5bn was about 2.9× operating income, flattered by an inventory release of KRW 11.0bn. Normalised OCF looks closer to KRW 15–20bn; TTM Jun 2026 was 20.7bn. Maintenance capex is light at about KRW 3–4bn a year, roughly 3–4% of revenue. Construction-in-progress of KRW 7.5–9.3bn (FY2023 to H1 2026) suggests ongoing facility work.

Ratios

Notes:

  • FY2025 interest expense was KRW 3.88bn (Valueline). TTM Jun 2026 interest coverage improves to about 3.9× (OP 9.23 / interest 2.35).

  • Valueline shows current ROE of 8.09% (Oct 2026).

Commentary. Every leverage and liquidity metric improved in FY2025. Return metrics are only now recovering to high single digits. Working-capital intensity is the structural weakness: about 150 days of receivables plus more than 120 days of inventory measured against sales, typical of implant makers that consign instrument and implant sets. It ties up roughly KRW 75bn, close to the company's entire market capitalisation.

Quarterly run-rate

Sources: Google Finance (DART-derived); company releases; Edaily; ChickStock (DART). Q1 2025 is from the company release.

Commentary. Earnings are back-half weighted: Q3–Q4 2025 delivered 76% of FY2025 OP. 1H 2026 OP of KRW 2.35bn compares with KRW 2.41bn in 1H 2025. Repeating FY2025 OP of KRW 9.0bn therefore needs a second half similar to H2 2025. The Q2 2026 consolidated net profit of KRW 1.12bn was described as a turnaround from a loss (Edaily, Jul 2026).

Unlock Company Financials

Unlock this company profile to view its financial data.

View Subscription Plans

Financial Detail

Group Entities

EntityRelationshipActivityStatus

Corentec Co., Ltd.

Parent (listed)

Orthopaedic implant R&D, manufacturing and sales

Active

Corentec America Inc.

Wholly owned subsidiary

US distribution of hip, knee and spine implants and instruments

Active (corentec-usa.com)

Sun Healthcare International Co., Ltd. (선헬스케어인터내셔널)

51.2% subsidiary since Jul 2022

B2B health-screening services, medical-device distribution, US ASC ownership

Active; CEO Lee Kyu-eun; about 35 staff (TheVC, Jun 2026)

Sun Surgery Center Huntington

Held via Sun Healthcare International

Outpatient joint-replacement ASC, Huntington Beach, CA; 700+ surgeries and procedures per year at acquisition

Active (Dealsite, Jul 2022)

Corentec China

Subsidiary established 2014

China sales

In liquidation since 2024 (Dailymedi)

Japan branch office

Branch

Japan market entry and surgeon network

Established before 2023 (KED Global)

Woosung Pharmaceutical

80% subsidiary May 2023 – Mar 2025

Injectable generics (acetaminophen IV infusions)

Divested to Sillajen, Mar 2025

Segment share of revenue (%)

Segment share of revenue (%)Q2 2026

Artificial joints

80

Medical-device wholesale

16

Info services and ASC

4

Implied segment revenue (KRW Bn)

Implied segment revenue (KRW Bn)Q2 2026

Artificial joints

20.6

Medical-device wholesale

4.1

Info services and ASC

1.0

Data Point Details

Data pointValueSource

Hip + knee share of revenue, Q1 2023

Hip KRW 6.4bn (38.8%), knee KRW 7.6bn (46.3%), together 85.1% as presented

Pharm Edaily, Apr 2023

Artificial-joint segment revenue guidance FY2025

KRW 77.8bn (+20% YoY)

Corentec/BioTimes, May 2025

Artificial joints' share of revenue at Mar 2023

More than 85%

SmartToday, Mar 2023

Woosung Pharmaceutical scale at divestment

About KRW 8bn revenue and KRW 1.2bn net profit per year

News1, Mar 2025

Income Statement and Margin Analysis (%)

MetricFY2021FY2022FY2023FY2024FY2025

Revenue (KRW Bn)

44.663.992.093.7100.4

Revenue growth YoY (%)

—43.344.01.87.2

Operating income (KRW Bn)

3.85.87.13.99.0

Operating margin (%)

8.59.17.74.29.0

Net income incl. NCI (KRW Bn)

0.82.75.1-1.37.0

Net margin (%)

1.84.25.5-1.46.9

D&A (KRW Bn)

————5.4

EBITDA (KRW Bn)

————14.4

EBITDA margin (%)

————14.4

EPS basic (KRW)

———-193—

Dividends per share (KRW)

00000

Unlock Company Financials

Unlock this company profile to view its financial data.

View Subscription Plans

Balance Sheet and Per-Share Data

MetricFY2022FY2023FY2024FY2025H1 2026

Total assets (KRW Bn)

171.8187.1186.3171.9165.1

Current assets (KRW Bn)

114.2115.5116.6111.9104.9

Cash and equivalents (KRW Bn)

15.717.117.217.823.1

Short-term financial assets (KRW Bn)

5.36.82.13.02.9

Trade receivables (KRW Bn)

31.440.438.142.139.2

Inventories (KRW Bn)

22.535.045.232.635.5

PP&E (KRW Bn)

37.244.745.338.637.6

Goodwill (KRW Bn)

3.84.24.23.83.8

Intangibles incl. goodwill (KRW Bn)

9.816.213.88.88.8

Short-term borrowings (KRW Bn)

13.415.621.418.418.9

Short-term bonds (KRW Bn)

0.00.023.74.80.0

Current portion of LT debt incl. bonds (KRW Bn)

14.025.21.31.68.8

Long-term borrowings (KRW Bn)

5.71.44.74.51.5

Convertible bonds, non-current (KRW Bn)

11.70.00.00.00.0

Total financial debt (KRW Bn)

44.842.151.129.329.3

Net debt (KRW Bn)

23.818.231.88.53.3

Total liabilities (KRW Bn)

96.6101.0101.882.871.0

Total equity (KRW Bn)

75.386.184.589.294.1

Equity attributable to owners (KRW Bn)

65.773.872.078.483.2

Non-controlling interests (KRW Bn)

9.512.412.510.810.9

Working capital (KRW Bn)

48.022.129.042.344.0

Book value per share (KRW)

5,0695,5145,3685,8446,205

Cash Flow

MetricFY2025TTM Jun 2026

Operating cash flow (KRW Bn)

26.4520.65

of which: decrease in inventories (KRW Bn)

10.974.12

Capex, PP&E (KRW Bn)

3.153.28

Capex, intangibles (KRW Bn)

0.440.96

Free cash flow, OCF minus capex (KRW Bn)

22.8616.41

Dividends paid (KRW Bn)

0.43—

Share buybacks (KRW Bn)

0.000.00

Bond repayments (KRW Bn)

28.9128.35

Returns & Leverage Ratios (%) and Financial Ratios (x)

RatioFY2022FY2023FY2024FY2025

ROE, net income / average total equity (%)

—6.3-1.58.1

ROA, net income / average total assets (%)

—2.8-0.73.9

Current ratio (x)

1.721.241.331.61

Debt / equity (x)

0.600.490.600.33

Liabilities / equity (%)

12811712193

Net debt / EBITDA (x)

———0.59

Interest coverage, OP / interest expense (x)

———2.3

Asset turnover (x)

—0.510.500.56

DSO, trade receivables / revenue × 365 (days)

180160149153

Inventory / revenue × 365 (days)

128139176119

Income Statement and Margin Analysis (%) (Quarterly)

MetricQ1 2025Q2 2025Q3 2025Q4 2025Q1 2026Q2 2026

Revenue (KRW Bn)

22.623.425.828.624.625.8

Operating income (KRW Bn)

1.01.43.73.20.91.5

Operating margin (%)

4.65.814.211.33.65.7

R&D expense (KRW Bn)

—0.980.910.781.01—

SG&A (KRW Bn)

—9.028.1810.049.24—

Gross margin (%)

—51.353.252.550.3—

Net income (KRW Bn)

2.7————1.1

Revenue by Region and Revenue by Region (%)

Region / market metricFY2022FY2023FY2024

US revenue (KRW Bn, approximate per company)

10.014.0—

Export share of revenue (%, approximate)

——40

Geography Overview

GeographyDisclosed factsTrend assessment

Korea

Hip share leader for seven straight years (as of 2023); No. 3 in knees

Stable, reimbursement-priced core

United States

FDA-cleared hip (2011), LOSPA II knee (2019), EXULT UCR (2025), spine; US revenue about KRW 14bn (2023); company targets UCR sales of USD 6.05M (2025) and 7.86M (2026); group owns a California ASC

Fastest-growing large market per company commentary; +33.1% YoY in Q2 2022

Mexico / Latin America

Entered 2017; company claims No. 2 share in Mexico after J&J; about USD 10M three-year supply contract (2023–2025); USD 15M MOU planned Nov 2025; Argentina active; Brazil approval targeted 2023; attended SBOT 2025 (Brazil)

Largest non-US export market per company; growing

Southeast Asia

Thailand and Indonesia among about 20 export countries

+327.7% YoY in Q2 2022 (with Latin America)

Japan

BENCOX hip MHLW approval (Jul 2023); branch office; JOA 2025 participation

Early-stage; Japan is about 50% of the APAC joint market per the company

India

CDSCO approvals (May 2022); three regional distributors

Early-stage

Middle East

Global Health Exhibition, Riyadh (Oct 2025)

Business development only

China

CFDA knee approval (2013); subsidiary founded 2014

Exited; liquidation decided 2024

Russia, Australia, Brazil

Named as expansion markets in 2022–2023

Status not disclosed

Share Price and Market Valuation

MetricFY2022FY2023FY2024FY2025

Year-end share price (KRW)

10,80011,8405,1106,700

Year-end market cap (KRW Bn)

133.4151.065.385.7

Book value per share (KRW)

5,0695,5145,3685,844

Price / book (x)

2.132.150.951.15

Shares outstanding (M)

12.3512.7612.7912.79

Valuation Multiples

MultipleCorentecBasis

P/E (TTM)

10.7×

Valueline

P/B

0.87×

Valueline (BPS ₩6,205, Jun 2026)

EV / EBITDA (TTM)

≈6.0×

EV ≈ KRW 86.2bn (market cap 72.0 + debt 29.3 − cash and short-term financial assets 26.0 + NCI 10.9) / TTM EBITDA ≈ 14.4

EV / Sales (TTM)

≈0.82×

TTM revenue KRW 104.8bn

ROE

8.1%

Valueline

Dividend yield

0%

No dividend

Change by Period

PeriodChangeBasis

Year to date 2026

-17.9%

₩6,700 (31 Dec 2025) → ₩5,500

Since end-2023 (about 2.8 years)

-53.5%

₩11,840 → ₩5,500

Since IPO (Mar 2013)

-65.6%

₩16,000 offer → ₩5,500

52-week range (as of Jul–Aug 2026)

₩3,385 – ₩7,440

Google Finance; Investing.com

Intra-2026 low point

₩4,150 at 30 Jun 2026

Valueline

Capital Markets

ItemStatus

Analyst consensus

None; no sell-side coverage found (StockHub reports 0 reports). The Korea IR Council research centre published sponsored-style estimates in 2023: FY2023E revenue KRW 88.5bn and OP KRW 6.9bn (Pharm Edaily, Apr 2023)

Dividend history and policy

No dividends paid; FY2025 elimination of the accumulated deficit (see §6.2) is a precondition for future distributions, but no policy has been announced

Buybacks

No company buyback programme. Insider open-market purchases by the Sun brothers in Dec 2021 – Feb 2022 (17,279 shares) and Sep 2022 (about KRW 300M) (Asia Economy; Bizwatch)

Credit ratings (Moody's, S&P, Fitch)

Not rated

Debt maturity profile (H1 2026)

Short-term borrowings KRW 18.9bn; current portion of LT debt KRW 8.8bn (of which bonds 4.9, LT loans 3.6); LT borrowings KRW 1.5bn. About 95% of financial debt is current. Bank lines are typically rolled; the 9th CB's final maturity is 10 Nov 2026

CB history

2016 KRW 20bn (repaid early 2019 after default); 8th KRW 15bn (Dec 2020); 9th KRW 20bn (Nov 2021, conversion price ₩14,534); bond repayments of KRW 28.9bn in FY2025

Analyst Conclusions

Guidance and consensus

Management guidance: No formal FY2026 consolidated guidance found. Product-level aspiration: EXULT UCR US sales of about USD 7.86M in 2026 and USD 10M+ in 2027.

Consensus: None; no sell-side coverage.

Run-rate: 1H 2026 revenue of KRW 50.4bn (+9% YoY) points to FY2026 revenue of about KRW 105–110bn if H2 follows the 2025 seasonality. This is analyst extrapolation, not a forecast from the company.

Bull case

  1. Normalised earnings power is higher than the 1H run-rate. H2 2025 OP of KRW 6.9bn (12.7% margin) shows what the implant core plus seasonal strength can deliver. Applying a 12% margin to about KRW 108bn of revenue would give about KRW 13bn of OP, roughly 5× EV.

  2. Balance-sheet repair unlocks optionality. Net debt fell from KRW 31.8bn to 3.3bn in 18 months and the accumulated deficit was cleared. The stock trades at 0.87× book with an 8% ROE, so modest ROE gains or a first dividend could re-rate it.

  3. Export levers are already funded. FDA (EXULT UCR), MHLW (BENCOX) and CDSCO approvals, the Biortotec USD 15M MOU and an experienced medtech CEO give multiple growth paths without new capital.

Bear case

  1. Governance instability destroys execution. Four CEO transitions since 2023 and repeated strategy reversals (pharma, China, dental) suggest strategy follows the controlling family rather than the CEO. CEO Hyun may not complete his term either.

  2. Structural competitive disadvantage. Without robotics and with about KRW 4bn of annual R&D, Corentec risks becoming a price-taker in the US against Zimmer Biomet (USD 8.2bn), Stryker (USD 9.5bn ortho) and Smith+Nephew. US UCR targets of USD 6–10M are small in absolute terms.

  3. Quality of earnings and working capital. FY2025 OCF was flattered by an inventory release of KRW 11.0bn. Receivables of about 150 days persist, and 1H 2026 OP (KRW 2.35bn) is no higher than 1H 2025. Subsidiaries are now diluting margins, and about 95% of debt is short-dated.

Catalysts and monitorables (next 12 months)

TimingCatalyst / monitorable
Nov 2026Q3 2026 results; test of H2 seasonal margin recovery (Q3 2025 OP margin was 14.2%)
10 Nov 20269th CB final maturity; watch for residual conversions or refinancing
Q4 2026 – Q1 2027First full-year strategy articulation under CEO Hyun; any formal medium-term targets
Feb – Mar 2027FY2026 preliminary results and business report; segment profitability; any dividend proposal at the 2027 AGM
OngoingEXULT UCR US sales against USD 7.86M (2026); Biortotec MOU conversion into binding orders; Japan and India first meaningful revenue
OngoingStrategic review of Sun Healthcare International (non-core, margin-dilutive)
OngoingInsider transactions (three reports in Jun 2026) and changes in share pledges

Analyst verdict

Corentec in late 2026 is a recovering, de-risked but still under-managed small-cap orthopaedic franchise.

Financial repair. The 2025 results mark a real inflection. Revenue crossed KRW 100bn for the first time, operating profit more than doubled to KRW 9.0bn, and net debt was cut to near zero by mid-2026. The balance-sheet crises of 2019 and 2024 have been neutralised: the convertible-bond default, the heavy short-term bond load and the KRW 51bn gross debt peak. At about 0.87× book, about 6× TTM EV/EBITDA and about 10.7× earnings, the market is not paying for the recovery.

Why the discount persists. The discount reflects three unresolved questions.

  1. Governance. No professional CEO has completed a term since 2023, and the controlling family's priorities have driven repeated strategic reversals. The appointment of Hyun Dong-wook, the first CEO with deep multinational medtech commercial credentials, is the most credible leadership choice in years. Investors will reasonably wait for evidence of tenure and a coherent plan.

  2. Competitive relevance. The company is strong in Korean hips and cost-competitive in emerging markets. Its R&D base (about 3.6% of sales) and lack of robotics limit its addressable share in the US, where growth expectations are concentrated.

  3. Earnings quality. Cash generation in 2025 relied on inventory release. Receivable days remain about 150, and subsidiaries are diluting margins.

Conclusion. On balance the risk/reward has shifted from distressed to value-with-catalysts. A clean H2 2026, meaning OP margins back above 10%, an orderly CB maturity and a first strategic communication from the new CEO, could close part of the discount to book. Further management turnover or a weak H2 would confirm the market's scepticism. Corentec warrants a monitoring position with event-driven triggers rather than a high-conviction call. The single most important variable is not the product portfolio but whether governance stabilises long enough for the export strategy to compound.

Unlock Company Financials

Unlock this company profile to view its financial data.

View Subscription Plans

Executive Leadership

Executive Leadership Team

NameTitleTenureBackgroundSource

Hyun Dong-wook (현동욱)

CEO and inside director

Since 31 Dec 2025

Medtronic Asia-Pacific sales and marketing roles and Korea head (1999–2004); Baxter Korea CEO (2004–2008); MSD Korea CEO; Baxter Korea president again from 2018 until resignation in Jul 2022; latterly Teleflex Medical MD; studied biology and biotechnology at the University of California

Dealsite; Etoday/Nate; DailyPharm

Park Hyung-chul (박형철)

Vice President

Acting CEO 14 Nov – 31 Dec 2025

—

Edaily; Digital Today

Kim Jung-sung (김정성)

Vice President

Acting CEO Apr – Jul 2024

—

Daum/ChosunBiz

“—” = not publicly disclosed.

Board of Directors

NameRoleNotes

Sun Doo-hoon (선두훈)

Inside director; founder

Orthopaedic surgeon; chairman of the Younghoon Medical Foundation (Sun Hospital, Daejeon); son-in-law of Hyundai Motor Group honorary chairman Chung Mong-koo (Etoday; Dailymedi)

Chung Sung-yi (정성이)

Inside director; largest individual shareholder

Advisor at Innocean Worldwide; eldest daughter of Chung Mong-koo; elder sister of Hyundai Motor Group chairman Chung Eui-sun (Investing.com KR 2020; Bloter 2024)

Sun Seung-hoon, Sun Kyung-hoon

Former co-CEOs (2020 – Mar 2023)

—

Outside directors

Three attended the 14 Nov 2025 board meeting

—

Major Shareholders

HolderStakeDate / source

Chung Sung-yi

7.41%

Q3 2025 (Etoday/Nate, Jan 2026)

Sun Doo-hoon

5.47%

Q3 2025 (same)

Largest shareholder plus related parties (total)

19.57%

Q3 2025 (same)

Sun Doo-hoon pledge

308,642 shares pledged to Shinhan Securities for a KRW 1.5bn loan

11 Oct 2023 (Dealsite, Feb 2024)

Sun Seung-hoon and Sun Kyung-hoon pledges

30,901 shares each for KRW 250M loans each

Dec 2020 (Investing.com KR)

9th CB holders (original)

Susung Asset Management and others

Dealsite, Oct 2021

2016 CB holders (redeemed 2019)

Coston and Premier growth-strategy M&A PEFs

Dealsite, Jul 2019

Competitive Landscape

Competitors by Segment

SegmentCompetitorHQRelative positioning vs Corentec

Hip and knee (global)

Zimmer Biomet

USA

Global No. 1 in recon; FY2025 knee USD 3.3bn and hip USD 2.1bn (Becker's, Feb 2026)

Hip and knee (global)

Stryker

USA

Orthopaedics USD 9.5bn (FY2025); Mako robotics leader

Hip and knee (global)

Johnson & Johnson (DePuy Synthes)

USA

—

Hip and knee (global)

Smith+Nephew

UK

Orthopaedics USD 2.44bn (FY2025); knee about USD 1.0bn and hip USD 641M; CORI robotics

Hip and knee (China/APAC)

MicroPort Orthopedics / MicroPort Scientific

China

Named as a competitor by PitchBook

Hip and knee (China)

AK Medical

China

China's largest domestic orthopaedic implant maker per the Yorkshire Evening Post

Hip and knee (Europe)

Lima Corporate (Enovis), Corin, Exactech

Italy / UK / USA

—

Korean orthopaedics

Osteonic, Hans Biomed, Huemedix

Korea

Listed as similar companies by TheVC

Korean spine

L&K Biomed, U&I Corp, Medyssey

Korea

—

Robotic arthroplasty (Korea)

Curexo (CUVIS-joint)

Korea

Robotics, a capability Corentec lacks

Peer Comparison FY2025

Metric (FY2025)CorentecZimmer BiometStrykerSmith+Nephew

Revenue (USD Mn)

71.88,23225,1006,164

Reported revenue growth (%)

7.27.211.26.1

Operating margin (%)

9.0——12.9

Net margin (%)

6.98.612.7—

R&D intensity (% of sales)

3.6—6.5—

Company Snapshot

$70.7M

Revenue

172

Employees

$50M

Market Cap

2000

Founded

Cheonan, South Korea

Headquarters

SWOT Analysis

Strengths

  • Domestic hip franchise. No. 1 Korean hip share for seven consecutive years (KED Global, Jul 2023).
  • Profit recovery delivered. FY2025 OP of KRW 9.0bn (9.0% margin), up from KRW 3.9bn in FY2024 (Butler; company release, Feb 2026).
  • Deleveraged balance sheet. Net debt fell from KRW 31.8bn (FY2024) to KRW 3.3bn (H1 2026); current ratio 1.72× (Valueline).
  • Global regulatory footprint. Clearances from the FDA (hip 2011, LOSPA II 2019, EXULT UCR 2025), Japan's MHLW (2023) and India's CDSCO (2022).
  • Proprietary surface technology. MAO (Otto Aufranc Award 2010) and DMT coatings; 96 patents (Corentec, Nov 2025).
  • Proven emerging-market traction. Claimed No. 2 in Mexico; Biortotec contracts of USD 10M (2023) and a USD 15M MOU (2025).

Weaknesses

  • Management churn. Four CEO changes and two acting-CEO periods between Mar 2023 and Dec 2025 (Etoday, Jan 2026).
  • Working-capital intensity. About 153 days of receivables and about 119 days of inventory relative to sales (FY2025, Valueline-derived).
  • Thin R&D. About KRW 3.7bn a year (3.6% of sales), against 6.5% at Stryker.
  • Low-margin non-core subsidiaries. Wholesale and services are about 20% of revenue, and management blamed subsidiaries for the Q1 2026 consolidated OP decline.
  • Earnings volatility. Quarterly OP margins ranged from 3.6% to 14.2% over the six quarters to Q2 2026.
  • Interest burden. FY2025 interest expense of KRW 3.88bn against OP of KRW 9.02bn (2.3× cover).

Opportunities

  • US knee growth. EXULT UCR company targets of USD 7.86M (2026) and USD 10M+ (2027).
  • Japan. BENCOX approved in a market the company describes as about half of APAC joint demand.
  • India. About 150,000 joint replacements a year, 80% imported; CDSCO approvals in hand.
  • Latin America. USD 15M Biortotec MOU; Brazil approval targeted; SBOT participation.
  • New indications. Total ankle and 3D-printed implants via national R&D programmes (TheVC).
  • Commercial depth under the new CEO. Hyun's multinational medtech background (Medtronic, Baxter, MSD, Teleflex) suits a distributor-led export model.

Threats

  • Robotics lock-in. Major peers tie implants to robotic platforms (Smith+Nephew CORI, Stryker Mako), which threatens Corentec in US accounts.
  • Pricing pressure. Reimbursement and tender pricing; China VBP precedent (Smith+Nephew FY2025 commentary) and Corentec's own China exit.
  • Distributor concentration. Heavy reliance on Biortotec in Mexico, its largest non-US export market.
  • Governance and financing history. FY2018 qualified audit opinion triggered a CB default in 2019 (Dealsite).
  • Dilution and overhang. Repeated CB financing (KRW 15bn in 2020; KRW 20bn in 2021) and a 2026 share-count increase of about 4.8%.
  • Currency. About 40% export share exposes margins to KRW/USD/MXN movements; FX losses of KRW 0.47bn in FY2025 (Valueline).

Unlock Company Financials

Unlock this company profile to view its financial data.

View Subscription Plans

Key Developments

DateEventSignificance
13–25 Mar 2025 (context)Woosung Pharmaceutical sold to Sillajen for KRW 10bn; payment completed 25 MarFunds deleveraging; ends pharma diversification
Apr 2025EXULT UCR insert launched in the USNew US growth vector
23 Apr 2025FDA clearance for EXULT Knee UCR; four-insert knee line-upBroadens surgeon appeal (works for PCL-retaining or PCL-sacrificing technique)
15 May 2025Q1 2025: revenue KRW 22.6bn (+18.8%), OP KRW 1.04bn, net profit KRW 2.7bn (turnaround); parent OP +366%Start of profitability recovery
May 2025FY2025 joint-segment target KRW 77.8bn (+20%)Only quantified segment target
2025Exhibits at JOA 2025 (Tokyo), WHX Miami (formerly FIME) and SBOT 2025 (Salvador, Brazil)Market development in Japan, US and Brazil
14 Aug 2025H1 2025 report: revenue +16.4% YoY; OP +1,961.5%; net profit turned positive (FnGuide summary)Confirms recovery
27–30 Oct 2025Global Health Exhibition, Riyadh: talks with Middle East hospitals and distributorsNew-region business development
14 Nov 2025Q3 2025 report: revenue KRW 25.8bn, OP KRW 3.65bn (14.2% margin)Strongest quarterly margin in the period
14 Nov 2025CEO Koo Bon-chul resigns for personal reasons; VP Park Hyung-chul acting CEOThird CEO change in three years
18 Nov 2025Planned USD 15M three-year MOU with Biortotec at KOTRA Global ConnectExtends Mexico anchor relationship
Nov 2025Two new knee patents filed; portfolio of 96 patents disclosedIP depth
20 Nov 2025Record date set for 31 Dec EGMProcedural
16 Dec 2025Record date (31 Dec 2025) set for 2026 AGMProcedural
31 Dec 2025EGM appoints Hyun Dong-wook (ex-Teleflex, Baxter, MSD, Medtronic) as CEOFirst CEO with deep medtech commercial experience
9 Jan 2026Press coverage of the CEO-turnover pattern; largest-shareholder group at 19.57%Governance overhang flagged
10 Feb 2026FY2025 preliminary: revenue KRW 100.4bn, OP KRW 9.02bn (+167.2% vs restated base); first year above KRW 100bnEarnings inflection confirmed
13 Feb 2026Samduk Accounting appointed auditor for FY2026–FY2028Auditor rotation or renewal
20 Mar 2026FY2025 business report filedAnnual filing
8 May 2026Q1 2026 preliminary: revenue KRW 24.6bn (+8.6%); consolidated OP down YoY because of subsidiariesSubsidiaries now a drag
15 May 2026Q1 2026 quarterly report filed—
5 and 11 Jun 2026Three insider and major-shareholder ownership-change reportsInsider activity
H1 2026Share count rises from 12.79M to 13.41MProbable CB conversion; about 4.8% dilution
24 Jul 2026Q2 2026 preliminary: revenue KRW 25.8bn (+10.1%), OP KRW 1.46bn (+6.3%), net profit KRW 1.12bn (turnaround)Steady growth; margin still sub-10%
14 Aug 2026H1 2026 report filed; segment mix 80/16/4Latest full disclosure
19 Oct 2026Shares at ₩5,500; market cap KRW 72.0bn; P/E 10.7×, P/B 0.87× (Valueline)Valuation reference point
Upcoming: 10 Nov 2026Maturity of the 9th CB (originally KRW 20bn; largely repaid or converted per balance sheet)Residual refinancing or conversion event

Financial Performance

Explore key financial metrics, segmented revenue, balance sheet health, and performance trends.

Revenue

4 charts
Implied Segment Revenue: Artificial joints was KRW 20,600 Mn in Q2 2026.
Corentec Co., Ltd. — Implied Segment Revenue
Series (KRW Mn)Q2 2026
Artificial joints20,600
Medical-device wholesale4,100
Info services and ASC1,000

Unlock Company Financials

Unlock this company profile to view its financial data.

View Subscription Plans

Sources

Sources

  1. Corentec Co., Ltd., corporate website notices, IR and news board (corentec.com): FY2025 results release (10 Feb 2026); auditor-appointment notice (13 Feb 2026) · EGM and AGM record-date notices (Nov–Dec 2025) · Biortotec MOU release (Nov 2025) · Q1 2025 results release (May 2025) · EXULT UCR FDA release (Apr 2025).
  2. Corentec IR presentation, "경영실적 및 주요 경영현황" (Oct 2018), via AlphaSquare. Financial data aggregators
  3. DART filings via Valueline/DataHero (consolidated balance sheet and cash flow, FY2022 – H1 2026; market data 19 Oct 2026).
  4. Butler (FY2021–FY2025 income statement; segment mix; disclosure list).
  5. FnGuide (margins, H1 2025 summary).
  6. Google Finance (quarterly P&L).
  7. ChickStock (Q2 2026 preliminary disclosure).
  8. Simply Wall St, Morningstar, Investing.com, Stockopedia, StockHub, PitchBook, CB Insights, TheVC (profile data). Korean press
  9. Dealsite: 2016, 2019, 2021, 2022, 2023, 2024, 2025, Dec 2025.
  10. Edaily / Pharm Edaily: 2013, 2019, 2022, 2023, 2024, Jul 2026.
  11. Etoday: 2013, 2022, 2023 · Nate, Jan 2026.
  12. Dailymedi: 2022, 2024, Nov 2025.
  13. Bloter, 2024: Daum/ChosunBiz, 2024.
  14. News1/Daum, Mar 2025: Medigate News, 2022 and 2025.
  15. Medical Today, Nov 2025: Digital Today, Nov 2025.
  16. SmartToday, 2023: KED Global, 2023 · Asia Economy, 2022 · Bizwatch, 2022 · AsiaToday, 2010 · Investing.com Korea, 2020 · DailyPharm, 2022. Industry and peer sources
  17. Becker's Spine: ODT (Corentec America launch).
  18. Peer data: Zimmer Biomet FY2025 8-K (Feb 2026) · Stryker FY2025 results and 10-K (Jan–Feb 2026) · Smith+Nephew FY2025 results (Mar 2026) · Becker's Spine peer summaries.

Company sources

Unlock Company Contacts

Connect with Key Decision-Makers

Access verified employee contacts and decision-maker information from this company to support your sales, lead generation, and business development efforts.